Product Name:
ERK1-pT202+pY204
Product Number:
ab-pk621
Target Full Name: Extracellular regulated protein-serine kinase 1 (p44 MAP kinase)
Target Alias: ERK-1; ERT2; Insulin-stimulated MAP2 kinase; Kinase ERK1; MAP kinase 1; MAPK 1; MAPK1; MAPK3; PRKM3; p44ERK1; p44MAPK; MGC20180; ENSG00000102882
Product Type Specific: Protein kinase phosphosite-specific antibody
Antibody Code: PK621
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: T202+Y204
Protein UniProt: P27361
Protein SigNET: P27361
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human ERK1 (MAPK3) sequence peptide Cat. No.: PE-04ACU90
Antibody Immunogen Sequence: L(pT)E(pY)VAT(bA)C
Antibody Immunogen Description: Corresponds to amino acid residues L201 to T207; In protein kinase catalytic domain activation T-loop between subdomains VII and VIII.
Production Method: Corresponds to amino acid residues L201 to T207; In protein kinase catalytic domain activation T-loop between subdomains VII and VIII.
Antibody Modification: Protein kinase phosphosite-specific antibody
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Strong immunoreactivity of a target-sized protein by Western blotting in HeLa cells treated with phenylarsine oxide and vanadate. Strong immunoreactivity with immunogen peptide on dot blots. Strong immunoreactivity with recombinant human ERK1 on protein dot blots.
Antibody Species Reactivity: Human
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 42-47 kDa.
Antibody Specificity: Very high
Antibody Cross Reactivity: Weak immunoreactivity on protein dot blots with recombinant human ERK2 and ERK5. No cross-reactivity in A431, A549, HepG2 and Jurkat cells, except for a strong ~170 kDa protein in Jurkat cells, which was also more weakly detected in A431 cells.
Related Product 1: ERK1-pT202+pY204 blocking peptide
Related Product 2: ERK1-3 pan-specific antibody (Cat. No.: AB-NK055-3)
Related Product 3: ERK1-III (ERK1-5) pan-specific antibody (Cat. No.: AB-NK055-5)
Related Product 4: ERK1-NT (ERK1-6) pan-specific antibody (Cat. No.: AB-NK055-6)
Related Product 5: ERK1-pS74 phosphosite-specific antibody (Cat. No.: AB-PK867)
Related Product 6: ERK1-pT207 phosphosite-specific antibody (Cat. No.: AB-PK865)
Related Product 7: ERK1-pY204 phosphosite-specific antibody (Cat. No.: AB-PK864)
Related Product 8: ERK1-pY204+pY207 phosphosite-specific antibody (Cat. No.: AB-PK866)
Related Product 9: ERKSelectideA - ERK1 (MAPK3) protein kinase substrate peptide
Related Product 10: ERKSelectideB - ERK1 (MAPK3) protein kinase substrate peptide
Scientific Background: ERK1 (MAPK3) is a protein-serine/threonine kinase of the CMGC group and MAPK family. It functions as a central component of the MAP kinase intracellular signalling pathway. Phosphorylation at T202 and Y204 by MEK1 and MEK2 increases its phosphotransferase activity. Depending on the cellular context, this pathway is involved in the regulation of cell growth, survival, adhesion, or differentiation. More than 500 substrates have been identified for these MAP kinases. ERK1 activation leads to its translocation from the cytosol to the nucleus where it can target substrate proteins involved in cell cycle regulation; Cyclin D1, suppression of apoptosis; BCL2 and BAD, tumour supression; p53, cell migration; PAI-1, and MHCII mediated immune response; PPARg1. ERK1 appears to be a tumour requiring protein (TRP). The active form of the protein kinase normally acts to promote tumour cell proliferation. Dysfunction of MAPK3 expression and activity has been observed in a variety of cancers. Predominantly over-expression of MAPK3 or constitutive activation has been observed in cancer cell lines. Generally, activation of MAPK3 does not appear to be due to mutations in the protein itself but rather aberrant signalling in upstream factors including Raf, Ras and epidermal growth factor receptor. MAPK3 may also have a role in promoting metastasis in invasive tumours. Mutations resulting in the activation of the MAPK3 protein, but not necessary the over-expression of the MAPK3 protein, have been associated with tumourigenesis in several cancer types.
